Status: Recruiting
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.
Participants needed: 447
Trial details
Phase: Phase 1, Phase 2Age: 30+Biological sex: AllType: InterventionalSponsor: Syndax PharmaceuticalsUpdated: Mar 18, 2026Locations: 57
Eligibility criteria
Arm A: Participants not receiving any strong CYP3A4 inhibitor/inducers or flucon... [+25]
Diagnosis of active acute promyelocytic leukemia. [+12]